Company Description
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States.
It operates through Pharmaceutical and Biotechnology segments. The company’s lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis.
It also develops VT-1908, a topical eye drop is an inosine 5′-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne.
In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform.
It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products.
The company is based in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Venkateswarlu Nelabhotla |
Contact Details
Address: Harvard Square, One Mifflin Place Cambridge, Massachusetts 02138 United States | |
| Phone | 973 832 8147 |
| Website | vyometx.com |
Stock Details
| Ticker Symbol | HIND |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001427570 |
| CUSIP Number | 92943X104 |
| ISIN Number | US92943X1046 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Venkateswarlu Nelabhotla M.B.A. | Co-Founder, Chief Executive Officer, President and Director |
| Dr. Shiladitya Sengupta M.Sc., Ph.D. | Co-Founder, Director and Member of Scientific and Clinical Advisory Board |
| Jerry Leonard C.P.A., M.B.A. | Chief Financial Officer, Principal Financial and Accounting Officer |
| Dr. Richard Fahrner Ph.D. | Chief Technology Officer |
| Jules Abraham | Investor Relations Officer |
| Dr. Charles G. Chavdarian Ph.D. | Senior Vice President of Product Development and Regulatory CMC |
| Dr. Tamara Agajanov M.D. | Senior Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 28, 2026 | 8-K | Current Report |
| Aug 25, 2026 | 8-K | Current Report |
| Aug 12, 2026 | 10-Q | Quarterly Report |
| May 29, 2026 | 8-K | Current Report |
| May 12, 2026 | 10-Q | Quarterly Report |
| Apr 29, 2026 | 8-K | Current Report |
| Mar 31, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 20, 2026 | PRE 14A | Other preliminary proxy statements |
| Mar 18, 2026 | 10-K | Annual Report |
| Feb 25, 2026 | 8-K | Current Report |